{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T16:35:23Z","timestamp":1788107723887,"version":"build-2803163510"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Epilepsy is a widespread disease requiring long-term drug treatment. The aim of this study was to collect information on reported suspected adverse drug reactions (sADRs) of antiseizure medications (ASMs) and study their seriousness and outcomes in various system organ classifications (SOCs). We intended to compare old and new ASMs\u2019 ADRs.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Using EudraVigilance (EV) database, we extracted line listings of reported sADRs with different ASMs over the period from January 2012 to December 2021. The list of ASMs was compiled according to the Anatomical therapeutic chemical classification system. The Medical Dictionary for Regulatory Activities version 24.0 was used for determining the SOCs of individual reported preferred terms (PTs) sADRs. In addition, we calculated the Reporting Odds Ratio (ROR), 95% confidence interval (95% CI), p-value (statistically significant if p&amp;lt; 0.05) and chi-square statistics.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 276,694 reports were contained in the exported line listings which included 1,051,142 individual sADRs reported as PTs such as seizure (3.49%), drug ineffective (2.46%), somnolence (1.32%), dizziness (1.29%) and represented four SOCs: nervous system disorders (19.26%), general disorders and administration site conditions (14.39%), psychiatric disorders (11.29%) and injury, poisoning and procedural complications (9.79). Among patients, the age group between 18 and 64\u00a0years had the highest percentage (52.40%), followed by those aged over 64\u00a0years (18.75%). Of all the reported PTs, 882,706 (83.98%) had reported seriousness. Old ASMs had a significant positive association with <jats:italic>\u201ccaused\/prolonged hospitalisation\u201d<\/jats:italic>, <jats:italic>\u201ccongenital anomaly\u201d<\/jats:italic>, <jats:italic>\u201cdisabling\u201d<\/jats:italic>, <jats:italic>\u201clife threatening\u201d<\/jats:italic> and <jats:italic>\u201cresults in death\u201d<\/jats:italic>, while new ASMS with <jats:italic>\u2018other medically important condition\u2019<\/jats:italic>. There were 386 (0.04%) PTs related to Sudden Unexpected Death in Epilepsy (SUDEP).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In our study, we examined 10\u00a0years\u2019 reported sADRs of ASMs in the EV international database. The majority of PTs were serious. Old ASMs were generally more commonly associated with undesired outcomes and seriousness. Considering their expected seriousness and outcomes, the safety profile of the different ASMs, can play a cardinal role in the selection of ASMs.<\/jats:p>","DOI":"10.3389\/fphar.2024.1411134","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:24:50Z","timestamp":1721795090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Seriousness and outcomes of reported adverse drug reactions in old and new antiseizure medications: a pharmacovigilance study using EudraVigilance database"],"prefix":"10.3389","volume":"15","author":[{"given":"Michael Magdy Fahmy","family":"Girgis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Farkasinszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e1ra","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"Vecserny\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"B\u00e1cskay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"B1","volume-title":"Screening for adverse reactions in EudraVigilance","author":"Agency","year":"2016"},{"key":"B2","volume-title":"Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions (Rev 4)","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00228-019-02678-1","article-title":"Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation","volume":"75","author":"Baftiu","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1159\/000508991","article-title":"COVID-19 infection and neurological complications: present findings and future predictions","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1528-1167.2009.02299.x","article-title":"Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis","volume":"51","author":"Beyenburg","year":"2010","journal-title":"Epilepsia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"key":"B7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.7727\/wimj.2013.251","article-title":"A review of pharmacovigilance","volume":"63","author":"Campbell","year":"2014","journal-title":"West Indian Med. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Collaborators","year":"2019","journal-title":"Lancet Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.yebeh.2008.01.003","article-title":"Modern management of epilepsy: a practical approach","volume":"12","author":"Elger","year":"2008","journal-title":"Epilepsy and Behav. E&B."},{"key":"B10","volume-title":"2021 annual report on EudraVigilance for the European parliament, the council and the commission","year":"2022"},{"key":"B11","volume-title":"EudraVigilance: electronic reporting","year":"2023"},{"key":"B12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"106547","DOI":"10.1016\/j.eplepsyres.2020.106547","article-title":"Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy","volume":"170","author":"Gesche","year":"2021","journal-title":"Epilepsy Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.eplepsyres.2022.106872","article-title":"Changes in the use of antiseizure medications in children and adolescents in Norway, 2009-2018","author":"Heger","year":"2022","journal-title":"Epilepsy Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3389\/fneur.2019.00427","article-title":"The outcome of status epilepticus and long-term follow-up","volume":"10","author":"Horv\u00e1th","year":"2019","journal-title":"Front. Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"106885","DOI":"10.1016\/j.eplepsyres.2022.106885","article-title":"Seizure exacerbation with anti-seizure medications in adult patients with epilepsy","volume":"181","author":"Jaramillo","year":"2022","journal-title":"Epilepsy Res."},{"key":"B17","volume-title":"Post-reform personal data protection in the European Union: general data protection regulation (EU) 2016\/679","author":"Krzysztofek","year":"2017"},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.eplepsyres.2011.02.012","article-title":"Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population","volume":"95","author":"Landmark","year":"2011","journal-title":"Epilepsy Res."},{"key":"B19","volume-title":"Liverpool COVID-19 interactions","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"L\u00f6scher","year":"2011","journal-title":"Epilepsia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0920-1211(02)00008-6","article-title":"Psychiatric complications in patients with epilepsy: a review","volume":"49","author":"Marsh","year":"2002","journal-title":"Epilepsy Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/epi4.12693","article-title":"Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel-modulating antiseizure medications","volume":"8","author":"Nightscales","year":"2023","journal-title":"Epilepsia Open"},{"key":"B24","volume-title":"Note for guidance \u2013 EudraVigilance Human \u2013 Processing of safety messages and individual case safety reports (ICSRs)","year":"2010"},{"key":"B25","volume-title":"Regulation 2018\/1725 on the protection of natural persons with regard to the processing of personal data by the EU institutions, bodies, offices and agencies","author":"Office","year":"2019"},{"key":"B26","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance medicines safety database: publicly accessible data for research and public health protection","volume":"41","author":"Postigo","year":"2018","journal-title":"Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"956825","DOI":"10.3389\/fimmu.2022.956825","article-title":"Capillary leak syndrome following COVID-19 vaccination: data from the European pharmacovigilance database Eudravigilance","volume":"13","author":"Ruggiero","year":"2022","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2509","DOI":"10.1212\/WNL.0000000000010874","article-title":"Pharmacologic treatment and SUDEP risk: a nationwide, population-based, case-control study","volume":"95","author":"Sveinsson","year":"2020","journal-title":"Neurology"},{"key":"B31","volume-title":"Effectiveness and safety of antiepileptic medications in patients with epilepsy","author":"Talati","year":"2011"},{"key":"B32","volume-title":"Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action","year":"2002"},{"key":"B33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr. Opin. neurology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1528-1167.2005.00411.x","article-title":"Sudden unexpected death in epilepsy: a review of incidence and risk factors","volume":"46","author":"Tomson","year":"2005","journal-title":"Epilepsia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1684\/epd.2014.0704","article-title":"The clinical pharmacology of traditional antiepileptic drugs","volume":"16","author":"Vajda","year":"2014","journal-title":"Epileptic Disord. Int. epilepsy J. videotape."},{"key":"B36","volume-title":"WHOCC - ATC\/DDD index","year":"2016"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1411134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:25:01Z","timestamp":1721795101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1411134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":36,"alternative-id":["10.3389\/fphar.2024.1411134"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1411134","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"article-number":"1411134"}}